Ategenos Pharmaceuticals

Ategenos Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of ligand-targeted therapies for cancer and other diseases. Founded by Dr. Philip Low, the company utilizes a proprietary platform to link high-affinity small molecule ligands to potent therapeutic payloads, enabling precise delivery to diseased cells. This approach is designed to maximize therapeutic efficacy while minimizing systemic toxicity and side effects. The company's lead program, AT-01, is a fibroblast activation protein (FAP)-targeted conjugate currently being evaluated for the treatment of various solid tumors. Ategenos operates out of the Purdue Research Park, maintaining strong ties to academic research in targeted drug delivery.